Nanobiotix Stock Hits New Record at €44.44, Soaring 1,313% Over One Year
Nanobiotix stock reached a new all-time high of €44.44 during the session this Tuesday, May 12, surpassing the previous peak of €44.18. The stock is trading at €43.60 mid-morning, up 3.22% from the previous day's close. The French biotech ranks third in gains on the SBF 120, an index that is down 0.58%.
A Stock Trajectory That Defies Comparison
Nanobiotix's progression is part of a dynamic of rare intensity. The stock has gained 64.4% over the week and 116.9% over three months. Over one year, the performance reaches 1,313%. Today's movement continues from the previous day's record of €41.52, which itself followed a peak of €38.40 reached on May 7. It's worth noting that the FDA approved an amendment to the Phase 3 NANORAY-312 study protocol on head and neck cancer in early May, a project led by Johnson & Johnson as the global sponsor. The company also presented preclinical data on its nanoprimer platform at the AACR on April 20. The session is unfolding contrary to the CAC 40 (-0.60% at 8,008 points) and the SBF 120 (-0.58%).
Technical Indicators in Extreme Territory
The stock is trading well above the upper Bollinger band set at €38.20, indicating a pronounced overbought configuration. The RSI at 80 confirms this reading, in characterized overbought territory. The gap with the 200-day moving average, located at €18.71, exceeds 130%, illustrating the magnitude of the bullish movement initiated since autumn. The technical resistance identified at €42.24 was breached during the session. No financial publications are scheduled in the immediate future, and a beta of 0.09 confirms that the movement remains largely decoupled from the Paris market.
